Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : Three Amigos Stock Thread -- Ignore unavailable to you. Want to Upgrade?

To: Ken W who wrote (28501)	4/24/2002 10:57:28 AM
From: JoeinIowa	Read Replies (1) \| Respond to of 29382

Ken, In mid-May we get results from their Alzheimers study. If they are good results my guess is a huge take off. The bottom line is this company has about a dozen irons in the fire that could ignite them. The biggest problem is cash and they have been selling shares to raise it. If something looks really promising I imagine they will pick up some type of equity partner. Stock has been on a steady rise since they announced the below article. Either someone knows the results or people just speculating. It is a good story and you can imagine the publicity they will get if they have good news. Joe NeoTherapeutics Announces Completion of Patient Dosing In Pivotal Clinical Trial of Neotrofin(TM) in Alzheimer's Disease Announcement of results anticipated by mid-May IRVINE, Calif., March 15 /PRNewswire-FirstCall/ -- NeoTherapeutics, Inc. (Nasdaq: NEOT - news) announced in a conference call yesterday that patient dosing in its pivotal clinical trial of Neotrofin(TM) in Alzheimer's disease has been completed. The Company expects to announce the results from the trial by mid-May 2002. The dosing of patients has been completed and the Company is now in the process of collecting, entering and auditing the patient data as it is received from the 51 clinical centers. Once the data has been fully entered and audited, the Company will break the blind and perform the analysis. The results of the study will then be reported. At this time, the trial data remains fully blinded, and no one knows which patients received Neotrofin and when they received placebo. ``We are proud of the job that our in-house clinical team has done in managing this important trial in an effective and efficient manner,'' stated Rajesh C. Shrotriya, President and Chief Operating Officer of NeoTherapeutics. ``Our clinical, compliance and regulatory team will have taken less than 13 months to enroll 521 patients, dose them for six months, enter and audit over 135,000 pages of data and perform the analysis.'' NeoTherapeutics seeks to create value for stockholders through the discovery and development of central nervous system (CNS) drugs, in-licensing and commercialization of anti-cancer drugs, and the licensing out of new drug targets discovered through genomics research. The Company has two drugs addressing major medical needs in pivotal/phase 3 stage of development: Neotrofin(TM) for Alzheimer's disease and satraplatin for prostate cancer. Additional neurology and anti-cancer drugs are in phase 1 and 2 human clinical trials and the Company has a rich pipeline of pre-clinical drug candidates. For additional information visit the Company's web site at www.neot.com. This press release may contain forward-looking statements regarding future events and the future performance of NeoTherapeutics that involve risks and uncertainties that could cause actual results to differ materially. These risks are described in further detail in the Company's reports filed with the Securities and Exchange Commission. Contacts: MEDIA RELATIONS Jon Siegal Ronald Trahan Associates (RTA) Inc. (508) 647-9782, ext. 15 INVESTOR RELATIONS John McManus NeoTherapeutics, Inc. (949) 788-6700, ext. 247

To: Ken W who wrote (28501)	4/24/2002 1:21:27 PM
From: Jibacoa	Respond to of 29382

Ken: MEOH is moving well.<g> I have to check if they will be able to add their product to the gasoline. The proposed law for gasoline additives seems that will be approved next week.<g> Of course Methanol is used in quite a few other things.<g> siliconinvestor.com siliconinvestor.com RAGL Bernard

To: Ken W who wrote (28501)	4/24/2002 1:29:14 PM
From: Jibacoa	Respond to of 29382

SBAC Some profit taking coming in.<g> I sold some of my position, but may buy it back.<g> Message 17368035 Message 17369123 siliconinvestor.com siliconinvestor.com Bernard